View Older Stories View More Recent Stories

Feb 23, 2023 07:00AM EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
Feb 23, 2023 07:00AM EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
Jan 3, 2023 08:00AM EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023 08:00AM EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 19, 2022 08:02AM EQRx (EQRX) Announces Acceptance of Marketing Authorization Application for Sugemalimab in UK
Dec 19, 2022 08:00AM EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
Dec 19, 2022 08:00AM EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
Dec 2, 2022 08:02AM EQRx (EQRX) Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
Dec 2, 2022 08:00AM EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
Dec 2, 2022 08:00AM EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
Nov 10, 2022 07:00AM EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
Nov 10, 2022 07:00AM EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
Nov 7, 2022 08:00AM EQRx to Participate in the Jefferies 2022 London Healthcare Conference
Nov 7, 2022 08:00AM EQRx to Participate in the Jefferies 2022 London Healthcare Conference
Oct 28, 2022 08:00AM EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022
Oct 28, 2022 08:00AM EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022
Aug 11, 2022 07:00AM EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
Aug 11, 2022 07:00AM EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
Aug 7, 2022 04:10AM EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lu
Aug 7, 2022 04:10AM EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lu
Jul 28, 2022 08:00AM EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 
Jul 28, 2022 08:00AM EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 
Jun 14, 2022 07:01AM EQRx (EQRX) Announces Acceptance of MAA by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
Jun 14, 2022 07:00AM EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
Jun 14, 2022 07:00AM EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
May 31, 2022 08:00AM EQRx to Participate at Upcoming Investor Conferences
May 31, 2022 08:00AM EQRx to Participate at Upcoming Investor Conferences
May 26, 2022 05:00PM EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022
May 26, 2022 05:00PM EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022
May 13, 2022 07:00AM EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress
May 13, 2022 07:00AM EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress
Apr 29, 2022 08:00AM EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022
Apr 29, 2022 08:00AM EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022
Apr 27, 2022 10:30AM EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting
Apr 27, 2022 10:30AM EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting
Mar 23, 2022 07:00AM EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress
Mar 23, 2022 07:00AM EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress
Mar 9, 2022 08:00AM EQRx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 23, 2022
Mar 9, 2022 08:00AM EQRx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 23, 2022
Mar 2, 2022 08:00AM EQRx to Participate in Cowen’s 42nd Annual Health Care Conference
Mar 2, 2022 08:00AM EQRx to Participate in Cowen’s 42nd Annual Health Care Conference
Jan 19, 2022 05:28AM EQRx (EQRX) Announces Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
Jan 18, 2022 07:00PM Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
Jan 18, 2022 07:00PM Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
Jan 18, 2022 08:00AM EQRx (EQRX) Announces Two Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer
Jan 18, 2022 08:00AM EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer
Jan 18, 2022 08:00AM EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer
Jan 10, 2022 07:34AM EQRx (EQRX) Enters MOU with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines
Jan 10, 2022 07:30AM EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines
Jan 10, 2022 07:30AM EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines
View More Recent Stories View Older Stories